Lv61
2760 积分 2023-03-27 加入
Evaluation of Cereblon-Directing Warheads for the Development of Orally Bioavailable PROTACs
1个月前
已完结
Discovery of Potent and Selective Covalent Inhibitors of HER2WT and HER2YVMA
2个月前
已完结
Cyclic Peptide Keap1–Nrf2 Protein–Protein Interaction Inhibitors: Design, Synthesis, and In Vivo Treatment of Acute Lung Injury
3个月前
已完结
Molecular Glue Discovery: Current and Future Approaches
3个月前
已完结
Recent Advances in Developing Targeted Protein Degraders
3个月前
已关闭
Emerging and Re-emerging Warheads for Targeted Covalent Inhibitors: An Update
3个月前
已完结
Discovery of Potent, Highly Selective, and Efficacious SMARCA2 Degraders
5个月前
已完结
Chemical Scaffolds for the Clinical Development of Mutant-Selective and Reversible Fourth-Generation EGFR-TKIs in NSCLC
5个月前
已完结
Discovery of Highly Selective Inhibitors of Microtubule-Associated Serine/Threonine Kinase-like (MASTL)
5个月前
已完结
A Phase I trial of BI 1810631, a HER2 tyrosine kinase inhibitor (TKI), as monotherapy in patients (pts) with advanced/metastatic solid tumors with HER2 aberrations
6个月前
已完结
皖公网安备34019202002308
